Dachaigh › Aillse Sgamhain Neo-chealla-beag › Pennsylvania › Lancaster
Sgrùdaidhean clionaigeach Aillse Sgamhain Neo-chealla-beag ann an Lancaster, PA
Tha 7 sgrùdaidhean airson Aillse Sgamhain Neo-chealla-beag a’ lorg phàirtichean aig làraichean ann agus timcheall air Lancaster (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
A’ fastadhÌre 3
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0134), Lancaster
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
A’ fastadhÌre 3
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0111), Lancaster
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
A’ fastadhÌre 3
- Lancaster General Hospital, Lancaster
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
A’ fastadhÌre 3
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0068), Lancaster
Pan-tumor MRD Study
A’ fastadhSgrùdadh amharc
- Lancaster General Hospital (UPenn), Lancaster
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
A’ fastadhÌre 3
- Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
A’ fastadhÌre 3
- Research Site, Lancaster
Sgrùdaidhean Aillse Sgamhain Neo-chealla-beag ann am bailtean eile
- Houston, TX145 sgrùdaidhean
- New York City, NY121 sgrùdaidhean
- Arlington, VA104 sgrùdaidhean
- Nashville, TN97 sgrùdaidhean
- Boston, MA90 sgrùdaidhean
- Los Angeles, CA87 sgrùdaidhean
- St. Louis, MO73 sgrùdaidhean
- Chicago, IL61 sgrùdaidhean
- Baltimore, MD60 sgrùdaidhean
- San Antonio, TX59 sgrùdaidhean
- Columbus, OH57 sgrùdaidhean
- Washington, DC55 sgrùdaidhean
Sgrùdaidhean eile ann an Lancaster
- Galarachd Cardiovasculach5 sgrùdaidhean
- Fàilligeadh a' Chridhe5 sgrùdaidhean
- Aillse a' bhroilleach4 sgrùdaidhean
- Aillse Prostata4 sgrùdaidhean
- Ailse metastatach4 sgrùdaidhean
- Ailseachadh nan Sgamhan3 sgrùdaidhean
- Amblyopia3 sgrùdaidhean
- Galair a' Chridhe3 sgrùdaidhean
- Aillse sa bhlaire3 sgrùdaidhean
- Aillse Blaodaire Neo-invasive3 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.